Corpus 1,272 assessed · 1,173 scored · 643 reproduced ≥75 · 168 flagged ·∅ 74.1/100

Publications 2 Datasets 392.5k Experiments 4.7k

Explore

Filters: Internal medicine ✕ clinical-trial ✕ clear all

2 matching publication(s)

Publication	Journal	Year	Score	Verdict
IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses. PMID 40128415	Breast Cancer	2025	71	L1 71/100
Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials. PMID 39090192	NPJ Precis Oncol	2024	50	L1 50/100

IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.

PMID 40128415 · Breast Cancer · 2025

L1 71/100

Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials.

PMID 39090192 · NPJ Precis Oncol · 2024

L1 50/100